PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI’s Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by a companion FOA, RFA-CA-17-003 ) and a single PDCCC (to be supported by this FOA). In addition, PDXNet will be supported by the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR). PDTCs and the PDCCC will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.

An applicant institution may submit only one application in response to this FOA.


  • Duke Internal: Jan. 9, 2017
  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): March 3, 2017

RFA-CA-17-004 Expiration Date March 4, 2017

Agency Website



Amount Description

Application budgets must reflect the actual needs of the proposed project but must not exceed $650,000 per year in direct costs.

The total project period for an application submitted in response to this FOA should be 5 years.  

Funding Type





Medical - Clinical Science
Medical - Translational

Internal Nomination

If you are interested in applying for this opportunity, please send the following in 1 PDF to Erin Carr at erin.carr@duke.edu by Monday, January 9th .

  • NIH biosketch
  • 2 page description of the project
  • Draft budget justification

All applicants will be notified no later than January 23rd.


Internal Deadline

January 9, 2017

External Deadline

March 3, 2017